Trial reportNutrition journal2026
Effects of L-BAIBA supplementation with and without grains of paradise on changes in resting metabolic rate, body composition, and cardiometabolic risk factors.
Trial report in Nutrition journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Strategies to augment weight loss, fitness, and body composition are in high demand. The myokine beta-amino-isobutyric acid (BAIBA) has been shown to increase fat loss, while grains of paradise (GOP), a member of the ginger family, may aid weight loss by reducing appetite and increasing thermogenesis.Purpose To evaluate the impact of 56 days of supplementing with L-BAIBA or L-BAIBA + GOP (BGOP) on resting metabolic rate, body composition, perceptual indicators of mood and affect, and cardiometabolic markers in overweight and obese men and women. MethodsHealthy men and women (43.2 ± 11.4 years, 169.4 ± 7.6 cm, 90.3 ± 15.6 kg, 31.4 ± 4.4 kg∙m-2) completed a weekly exercise program and followed a calorie-restrictive diet and were randomly assigned in a double-blind and blocked manner according to sex and DXA lean mass to consume daily either a placebo (PLA) (n=12 [11F, 1M]), 500 mg L-BAIBA (L-BAIBA: MitoBurn™, NNB Nutrition) (n=13 [9F, 4M]), or 500 mg L-BAIBA + 40 mg GOP (BGOP: CaloriBurn™, NNB Nutrition) (n=12 [8F, 4M]). After 0, 14, 28, and 56 days of supplementation, participants were evaluated for changes in body mass, body composition using dual-energy x-ray absorptiometry (DXA), resting metabolic rate, perceptual indicators of hunger, appetite, energy, focus, attention, and concentration using 100-mm anchored visual analog scales (VAS) and mood using the Profile of Mood States along with evaluation of selected cardiometabolic markers. Dietary intake was evaluated using 3-day dietary recalls using ASA24 throughout the study. Mixed factorial ANOVAs with repeated measures assessed the main and interaction effects. A p-value of 0.05 was used to determine statistical outcomes.ResultsNo statistically significant group × time interactions (p>0.05) were found for body mass, resting metabolic rate, DXA fat mass, DXA fat-free mass, DXA % fat, VAS ratings for appetite, energy, focus, attention, and concentration, resting heart rate, systolic blood pressure, diastolic blood pressure, glucose, or lipid panel component. A significant group × time interaction (p = 0.011) for hunger VAS ratings was observed. Compared with PLA, BAIBA reported reduced hunger ratings after 14, 28, and 56 days of supplementation, while BGOP reported reduced hunger ratings after 28 days of supplementation. Conclusion Despite no accompanying changes in body composition, resting metabolic rate, or dietary intake, supplementation with BAIBA and BGOP reduced perceived hunger compared to PLA during the diet and exercise program.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.